Genematrix Pushes Back GMAI-02 Phase 1 Trial Expected Completion to August 2028

Bitget2026/10/27 02:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Genematrix’s Oct. 27, 2026, correction moved the GMAI-02 Phase 1 trial’s expected completion to Aug. 28, 2028, from June 30, 2027.
The revised date reflects the clinical trial contract’s end date.
Seoul National University Hospital was confirmed as the trial site; C&R Research will serve as the contract research organization.
The hepatitis A vaccine trial targets 30 healthy adult men in South Korea.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genematrix Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261027900143), on October 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03